Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects

NCT03324061 is registered in ClinicalTrials.gov with Eagle Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03324061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03324061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects
Lead sponsor
Eagle Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2017
Completion date
July 12, 2018
Enrollment
600 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics